QED Pharmaceutical Services has licensed SAS® Clinical Data Integration to enable its drug development clients to more easily form partnerships with key biopharmaceutical companies. SAS offers a comprehensive portfolio of life sciences software solutions for pharmaceutical, biotechnology and medical device companies.
“The availability of SAS Clinical Data Integration has made it possible for QED to efficiently implement complex data standards such as the CDISC standards,” said Dr. Ramana Kuchibhatla, QED founder. “This allows us to help our clients - predominantly small and sometimes virtual biopharmaceutical companies - achieve important milestones despite their size. Compliance with the latest CDISC standards makes growing drug developers like our clients very attractive partners to large pharma companies that are looking to in-license successful drug development programs. ”
QED also uses other SAS products including SAS® Enterprise Business Intelligence. With the knowledge base created by these systems, QED can offer cost-effective services for its clients. “It’s as if we have designed an efficient mechanical engine, and now, with little modification for each clinical trial, we can crank out CDISC-compliant data and get our clients’ datasets output in regulatory submission-ready formats,” said Kuchibhatla.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.